Skip to main content

MZM Disease Interactions

There are 11 disease interactions with MZM (methazolamide).

Major

Carbonic anhy. inhibitors (applies to MZM) bone marrow depression/blood dyscrasias

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, History - Blood Dyscrasias

The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages. Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions. A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.

Switch to professional interaction data

Major

Carbonic anhyd. inhibitors (applies to MZM) adrenal insufficiency

Major Potential Hazard, Moderate plausibility.

The use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency. The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients. Monitoring electrolyte levels is recommended.

Switch to professional interaction data

Major

Carbonic anhyd. inhibitors (applies to MZM) closed-angle glaucoma

Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

The use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma. Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure. Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.

Switch to professional interaction data

Major

Carbonic anhydrase inhibitors (applies to MZM) hypokalemia

Major Potential Hazard, Moderate plausibility.

The use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia . Carbonic anhydrase inhibitors may cause increased potassium excretion. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.

Switch to professional interaction data

Major

Carbonic anhydrase inhibitors (applies to MZM) hyponatremia

Major Potential Hazard, Moderate plausibility.

The use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia . Carbonic anhydrase inhibitors may cause sodium excretion. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.

Switch to professional interaction data

Major

Carbonic anhydrase inhibitors (applies to MZM) severe kidney disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease. Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.

Switch to professional interaction data

Major

Carbonic anhydrase inhibitors (applies to MZM) severe liver disease

Major Potential Hazard, Moderate plausibility.

The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis. Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased. A dose reduction might be needed and monitoring of the liver function is recommended.

Switch to professional interaction data

Moderate

Carbonic anhydr. inhibitors (applies to MZM) respiratory acidosis

Moderate Potential Hazard, Low plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.

Switch to professional interaction data

Moderate

Carbonic anhydrase inhibitors (applies to MZM) diabetes mellitus

Moderate Potential Hazard, Low plausibility.

Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.

Switch to professional interaction data

Moderate

Carbonic anhydrase inhibitors (applies to MZM) gout

Moderate Potential Hazard, Moderate plausibility.

Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.

Switch to professional interaction data

Moderate

Carbonic anhydrase inhibitors (applies to MZM) metabolic acidosis

Moderate Potential Hazard, Moderate plausibility.

Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea). The measurement of baseline and periodic serum bicarbonate is recommended. If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.

Switch to professional interaction data

MZM drug interactions

There are 229 drug interactions with MZM (methazolamide).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.